SHREWSBURY, United Kingdom, July 16, 2025 (GLOBE NEWSWIRE) -- Lightchain AI a decentralized infrastructure protocol focused on artificial intelligence, has confirmed the launch of its mainnet in July 2025. This milestone marks a significant step forward in integrating AI execution into blockchain environments through real-time task processing, developer tools, and incentive-driven consensus.
DUBAI, United Arab Emirates, Dec. 08, 2025 (GLOBE NEWSWIRE) -- AstroX Finance has officially opened its groundbreaking livestream-powered multichain platform, marking one of the most significant advancements in Web3 creator infrastructure to date. Positioned at the intersection of real-time entertainment, multichain tokenization, and AI-driven creator monetization, AstroX is redefining how meme tokens are launched, traded,…
Frontline plc (the “Company”) advises that the 2025 Annual General Meeting of the Shareholders of the Company was held on 8 December 2025 at 09:00 a.m. at Metis Tower, 28th October Avenue and Iakovou Tombazi Street, 4th floor, 3107 Limassol, Cyprus. The audited consolidated financial statements for the Company for the year ended 31 December…
PORT WASHINGTON, N.Y., Dec. 08, 2025 (GLOBE NEWSWIRE) -- What are the most common household pests in Port Washington, and how can homeowners keep them out? That question is answered in a HelloNation article featuring insights from Steven Moore of Hubert Moore Exterminator LLC. The piece highlights the challenges homeowners face, especially those living in older,…
NEWPORT BEACH, Calif., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Caleb Downs from The Ohio State University has been named winner of the Lott IMPACT® Trophy presented by Allied Universal®. A junior safety for the Buckeyes, Downs is a reigning national champion and previous Lott Trophy finalist. He led the Buckeyes to another Big Ten title…
NEW YORK, Dec. 07, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that clinical data from its ongoing Phase 2 study of SLS009, a highly selective CDK9…
